Characterization of β-D-N4-hydroxycytidine as a novel inhibitor of Chikungunya virus

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 4, 2017, Pages

  Ehteshami, Maryam ^a   Tao, Sijia ^a   Zandi, Keivan ^a,b   Hsiao, Hui Mien ^a   Jiang, Yong ^a   Hammond, Emily ^a   Amblard, Franck ^a   Russell, Olivia O ^a   Merits, Andres ^c   Schinazi, Raymond F ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MALAYA   (Malaysia)

^c UNIVERSITY OF TARTU   (Estonia)

Author keywords

Antiviral agents; Chikungunya virus; Nucleoside analogs; Replicon

Indexed keywords

ANTIVIRUS AGENT; BETA DETRO N 4 HYDROXYCYTIDINE; FAVIPIRAVIR; NUCLEOSIDE ANALOG; RIBAVIRIN; UNCLASSIFIED DRUG; CYTIDINE; N(4)-HYDROXYCYTIDINE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BHK CELL LINE; CHIKUNGUNYA VIRUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG METABOLISM; EC50; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; REPLICON; REPLICON CELL; VERO CELL LINE; VIRUS INHIBITION; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; ANIMAL; CELL LINE; DRUG EFFECTS; HUMAN;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CHIKUNGUNYA VIRUS; CYTIDINE; HUMANS; VIRUS REPLICATION;

EID: 85016935885     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02395-16     Document Type: Article

References (26)

1. Lo Presti A, Cella E, Angeletti S, Ciccozzi M. 2016. Molecular epidemiology, evolution and phylogeny of Chikungunya virus: an updating review. Infect Genet Evol 41:270-278. https://doi.org/10.1016/j.meegid.2016.04.006.
2. Madariaga M, Ticona E, Resurrecion C. 2016. Chikungunya: bending over the Americas and the rest of the world. Braz J Infect Dis 20:91-98. https://doi.org/10.1016/j.bjid.2015.10.004.
3. van Duijl-Richter MK, Hoornweg TE, Rodenhuis-Zybert IA, Smit JM. 2015. Early events in Chikungunya virus infection - from virus cell binding to membrane fusion. Viruses 7:3647-3674. https://doi.org/10.3390/v7072792.
4. Couderc T, Lecuit M. 2015. Chikungunya virus pathogenesis: from bedside to bench. Antiviral Res 121:120-131. https://doi.org/10.1016/j.antiviral.2015.07.002.
5. Abdelnabi R, Neyts J, Delang L. 2015. Towards antivirals against chikungunya virus. Antiviral Res 121:59-68. https://doi.org/10.1016/j.antiviral.2015.06.017.
6. Salazar-Gonzalez JA, Angulo C, Rosales-Mendoza S. 2015. Chikungunya virus vaccines: current strategies and prospects for developing plantmade vaccines. Vaccine 33:3650-3658. https://doi.org/10.1016/j.vaccine.2015.05.104.
7. McSweegan E, Weaver SC, Lecuit M, Frieman M, Morrison TE, Hrynkow S. 2015. The Global Virus Network: challenging chikungunya. Antiviral Res 120:147-152. https://doi.org/10.1016/j.antiviral.2015.06.003.
8. Thiboutot MM, Kannan S, Kawalekar OU, Shedlock DJ, Khan AS, Sarangan G, Srikanth P, Weiner DB, Muthumani K. 2010. Chikungunya: a potentially emerging epidemic? PLoS Negl Trop Dis 4:e623. https://doi.org/10.1371/journal.pntd.0000623.
9. Henss L, Beck S, Weidner T, Biedenkopf N, Sliva K, Weber C, Becker S, Schnierle BS. 2016. Suramin is a potent inhibitor of Chikungunya and Ebola virus cell entry. Virol J 13:149. https://doi.org/10.1186/s12985-016-0607-2.
10. Karlas A, Berre S, Couderc T, Varjak M, Braun P, Meyer M, Gangneux N, Karo-Astover L, Weege F, Raftery M, Schonrich G, Klemm U, Wurzlbauer A, Bracher F, Merits A, Meyer TF, Lecuit M. 2016. A human genome-wide loss-of-function screen identifies effective chikungunya antiviral drugs. Nat Commun 7:11320. https://doi.org/10.1038/ncomms11320.
11. Albulescu IC, van Hoolwerff M, Wolters LA, Bottaro E, Nastruzzi C, Yang SC, Tsay SC, Hwu JR, Snijder EJ, van Hemert MJ. 2015. Suramin inhibits chikungunya virus replication through multiple mechanisms. Antiviral Res 121:39-46. https://doi.org/10.1016/j.antiviral.2015.06.013.
12. Delang L, Segura Guerrero N, Tas A, Querat G, Pastorino B, Froeyen M, Dallmeier K, Jochmans D, Herdewijn P, Bello F, Snijder EJ, de Lamballerie X, Martina B, Neyts J, van Hemert MJ, Leyssen P. 2014. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J Antimicrob Chemother 69:2770-2784. https://doi.org/10.1093/jac/dku209.
13. Bourjot M, Leyssen P, Neyts J, Dumontet V, Litaudon M. 2014. Trigocherrierin A, a potent inhibitor of chikungunya virus replication. Molecules 19:3617-3627. https://doi.org/10.3390/molecules19033617.
14. Das PK PL, Varghese FS, Utt A, Ahola T, Kananovich DG, Lopp M, Merits A, Karelson M. 2016. Design and validation of novel chikungunya virus protease inhibitors. Antimicrob Agents Chemother 60:7382-7395. https://doi.org/10.1128/AAC.01421-16.
15. Ravichandran R, Manian M. 2008. Ribavirin therapy for Chikungunya arthritis. J Infect Dev Ctries 2:140-142. https://doi.org/10.3855/T2.2.140.
16. Hernandez-Santiago BI, Beltran T, Stuyver L, Chu CK, Schinazi RF. 2004. Metabolism of the anti-hepatitis C virus nucleoside beta-D-N4-hydroxycytidine in different liver cells. Antimicrob Agents Chemother 48:4636-4642. https://doi.org/10.1128/AAC.48.12.4636-4642.2004.
17. Pohjala L, Utt A, Varjak M, Lulla A, Merits A, Ahola T, Tammela P. 2011. Inhibitors of alphavirus entry and replication identified with a stable Chikungunya replicon cell line and virus-based assays. PLoS One 6:e28923. https://doi.org/10.1371/journal.pone.0028923.
18. Lani R, Hassandarvish P, Chiam CW, Moghaddam E, Chu JJ, Rausalu K, Merits A, Higgs S, Vanlandingham D, Abu Bakar S, Zandi K. 2015. Antiviral activity of silymarin against chikungunya virus. Sci Rep 5:11421. https://doi.org/10.1038/srep11421.
19. Chiam CW, Chan YF, Loong SK, Yong SS, Hooi PS, Sam IC. 2013. Real-time polymerase chain reaction for diagnosis and quantitation of negative strand of chikungunya virus. Diagn Microbiol Infect Dis 77:133-137. https://doi.org/10.1016/j.diagmicrobio.2013.06.018.
20. Ehteshami M, Tao S, Ozturk T, Zhou L, Cho JH, Zhang H, Amiralaei S, Shelton JR, Lu X, Khalil A, Domaoal RA, Stanton RA, Suesserman JE, Lin B, Lee SS, Amblard F, Whitaker T, Coats SJ, Schinazi RF. 2016. Biochemical characterization of the active anti-hepatitis C virus metabolites of 2,6-diaminopurine ribonucleoside prodrug compared to sofosbuvir and BMS-986094. Antimicrob Agents Chemother 60:4659-4669. https://doi.org/10.1128/AAC.00318-16.
21. Han Z, Wyche JH. 1994. Guanosine induces necrosis of cultured aortic endothelial cells. Am J Pathol 145:423-427.
22. Wu LF, Li GP, Feng JL, Pu ZJ. 2006. Molecular mechanisms of adenosine-induced apoptosis in human HepG2 cells. Acta Pharmacol Sin 27:477-484. https://doi.org/10.1111/j.1745-7254.2006.00302.x.
23. Varghese FS, Rausalu K, Hakanen M, Saul S, Kummerer BM, Susi P, Merits A, Ahola T. 19 December 2016. Obatoclax inhibits alphavirus membrane fusion by neutralizing the acidic environment of endocytic compartments. Antimicrob Agents Chemother https://doi.org/10.1128/AAC.02227-16.
24. Ahmadi A, Hassandarvish P, Lani R, Yadollahi P, Jokar A, Bakar SA, Zandi K. 2016. Inhibition of chikungunya virus replication by hesperetin and naringenin. RSC Adv 6:69421-69430. https://doi.org/10.1039/C6RA16640G.
25. Sledziewska-Gojska E, Janion C. 1983. Do DNA repair systems affect N4-hydroxycytidine-induced mutagenesis? Acta Biochim Pol 30:149-157.
26. Stuyver LJ, Whitaker T, McBrayer TR, Hernandez-Santiago BI, Lostia S, Tharnish PM, Ramesh M, Chu CK, Jordan R, Shi J, Rachakonda S, Watanabe KA, Otto MJ, Schinazi RF. 2003. Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob Agents Chemother 47:244-254. https://doi.org/10.1128/AAC.47.1.244-254.2003.